All In MedTech

Device Trial Radar · NCT03297125

Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI

Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Dec 1, 2017

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Medical College of WisconsinAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 29, 2017

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this prospective, nonrandomized controlled phase IV study is to compare standard and advanced MRI for their ability to predict response to Optune therapy.

Conditions

  • Glioblastoma

Interventions

  • Standard Magnetic Resonance Imaging (MRI)Device

    Standard MRI.

  • Advanced MRI.Device

    Perfusion and diffusion MRI.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival.Time frame: Six months.
  2. Overall survival.Time frame: One year.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Froedtert Hospital & Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.